Drug intelligence / Profile preview

OssiGraft Prime

Development stage: Unknown
Lead developer: Ossium Health
Modality: Cell Therapies
Administration: Surgical Implantation

Overview

OssiGraft Prime is a premium cryopreserved viable bone matrix (VBM) allograft designed for the repair, replacement, and reconstruction of musculoskeletal defects in the spine, pelvis, and extremities. Developed by Ossium Health, it represents a second-generation orthobiologic that improves upon the original OssiGraft by incorporating processing advancements that result in a cohesive, gum-like consistency for better handling. The product is derived from vertebral bone sources of organ donors (median age 35) and contains a high proportion of cancellous bone to facilitate rapid bone regeneration. It is used in orthopedic and spine surgeries to fill bone voids and promote healing.

Brand names: OssiGraft Prime
Other names: OssiGraft Prime Viable Bone MatrixOssiGraft Prime VBM

Beyond the preview

Go deeper on OssiGraft Prime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OssiGraft Prime.

Explore the full profile